Helix 11 Dynamics Is Critical for Constitutive Androstane Receptor Activity  by Wright, Edward et al.
Structure
ArticleHelix 11 Dynamics Is Critical
for Constitutive Androstane Receptor Activity
Edward Wright,1,3 Scott A. Busby,2,3 Sarah Wisecarver,1 Jeremy Vincent,1 Patrick R. Griffin,2 and Elias J. Fernandez1,*
1Biochemistry, Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA
2Department of Molecular Therapeutics, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA
3These authors contributed equally to this work
*Correspondence: elias.fernandez@utk.edu
DOI 10.1016/j.str.2010.11.008SUMMARY
The constitutive androstane receptor (CAR) transac-
tivation can occur in the absence of exogenous
ligand and this activity is enhanced by agonists
TCPOBOP and meclizine. We use biophysical and
cell-based assays to show that increased activity of
CAR(TCPOBOP) relative to CAR(meclizine) corre-
sponds to a higher affinity of CAR(TCPOBOP) for the
steroid receptor coactivator-1. Additionally, steady-
state fluorescence spectra suggest conformational
differences between CAR(TCPOBOP):RXR and CAR
(meclizine):RXR. Hydrogen/deuterium exchange
(HDX) data indicate that the CAR activation function
2 (AF-2) is more stable in CAR(TCPOBOP):RXR and
CAR(meclizine):RXR than in CAR:RXR. HDX kinetics
also show significant differences between CAR
(TCPOBOP):RXR and CAR(meclizine):RXR. Unlike
CAR(meclizine):RXR, CAR(TCPOBOP):RXR shows
a higher overall stabilization that extends into RXR.
We identify residues 339–345 in CAR as an allosteric
regulatory site with a greater magnitude reduction in
exchange kinetics in CAR(TCPOBOP):RXR than CAR
(meclizine):RXR. Accordingly, assays with mutations
on CAR at leucine-340 and leucine-343 confirm this
region as an important determinant of CAR activity.
INTRODUCTION
Nuclear receptors (NRs) are multidomain transcription factors
that play a vital role in growth, development, and homeostasis
(Mangelsdorf et al., 1995). These proteins consist of an
N-terminal activation function-1 (AF-1), a central DNA-binding
domain (DBD), and a C-terminal ligand-binding domain (LBD)
which encompasses the activation function-2 (AF-2). X-ray
structures of all NR LBDs determined to date exhibit a common
three-dimensional fold. The C-terminal LBD encloses the ligand-
binding pocket (LBP) within a 12 a helix framework (Moras and
Gronemeyer, 1998; Wurtz et al., 1996). The ultimate helix H12,
also the ligand-dependent activation function 2 (AF-2) of the
LBD, plays a critical role in the recruitment of coactivator and
corepressor molecules. NRs utilize a common agonist-mediated
repositioning of helix H12 to generate the coactivator-bindingStructure 19,groove (Glass et al., 1997). However, differences in levels of tran-
scriptional activity in response to various agonists of the same
receptor suggest that agonists can fine-tune the conformation
of the coactivator-binding groove and consequently the affinity
of the activated receptor for coactivator proteins (Bourguet
et al., 2000; Gangloff et al., 2001; Oberfield et al., 1999).
CAR plays key roles in the clearance of xenobiotics (Sonoda
et al., 2003; Wei et al., 2000) and endogenous toxins such as
bilirubin (Huang et al., 2003). In addition, this protein has pharma-
cological importance due to its role in drug-to-drug interactions
(Chang andWaxman, 2006). Also, prolonged CAR activation has
been observed to enhance the progression of liver cancer
(Huang et al., 2005). For optimal function, CAR heterodimerizes
with the retinoid X receptor (RXR) and the CAR:RXR heterodimer
can transactivate retinoic acid response elements (RAREs) in an
apparent ligand-independent manner (Baes et al., 1994; Choi
et al., 1997). Transactivation by murine CAR is further enhanced
by agonist ligands such as 1,4-bis[2-(3,5-dichloropyridyloxy)]
benzene (TCPOBOP) (Tzameli et al., 2000) and 1-[(4-chloro-
phenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine (meclizine)
(Huang et al., 2004) (Figure 1A). Activated CAR recruits coactiva-
tor proteins such as the steroid receptor coactivator-1 (SRC1) by
interacting specifically with receptor interacting domain (RID) 2
of SRC1 (Dussault et al., 2002). Androstane metabolites such
as androstenol (5a-androst-16-en-3a-ol) have been identified
as the physiological inverse agonist ligands of murine CAR
(Forman et al., 1998). Androstenol binds to the CAR ligand-
binding domain (LBD) where it displaces helix H12 (AF2) from
the active-state conformation required to recruit coactivator
proteins (Shan et al., 2004). Incidentally, meclizine is also a ligand
for the human CAR isoform, where it functions as an inverse
agonist (Huang et al., 2004).
Here, we report a comparative study of the role of two agonists
of murine CAR. We compare CAR transactivation and coactiva-
tor binding affinities in response to the agonists TCPOBOP
and meclizine. Further, we utilize fluorescence spectroscopy,
HDX and site-specific mutagenesis to identify distinct CAR alter-
ations in conformational dynamics induced upon binding either
TCPOBOP or meclizine.
RESULTS
Comparing Transactivation and Coactivator Binding
by CAR(TCPOBOP) and CAR(meclizine)
Meclizine has been identified as an mCAR agonist in a high-
throughput screen and confirmed by a reporter gene assay using37–44, January 12, 2011 ª2011 Elsevier Ltd All rights reserved 37
Figure 1. Comparison of the Two CAR Ligands Used in This Study
(A) The chemical structures of CAR and TCPOBOP are shown.
(B) TCPOBOP is a more potent agonist in cell-based reporter gene assays
using the bRE response element. The data is shown in relative luciferase units
(RLU).
(C) TCPOBOP promotes higher affinity for coactivator than meclizine in ITC
experiments.
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Critical Helix 11 Dynamics in CARthe LXRE response element in HepG2 cells (Huang et al., 2004).
Also, in these experiments TCPOBOP is observed to exert
a stronger agonist response from CAR than meclizine. Reporter
gene assays with a second response element, bRE in CV-1
cells, confirm that TCPOBOP induces higher CAR transactiva-
tion than meclizine, independent of the DNA hormone response
element or cell line (Figure 1B). To compare the recruitment
of coactivator protein by CAR(TCPOBOP):RXR and CAR(mecli-
zine):RXR, we measured SRC1 binding to ligand-bound
CAR using ITC. Quantitative analyses of binding isotherms
show that at saturating concentrations of meclizine the affinity38 Structure 19, 37–44, January 12, 2011 ª2011 Elsevier Ltd All rightfor coactivator is less than CAR(TCPOBOP) (Figure 1C). The
thermodynamic parameters for recruitment of SRC1 NR2
peptide are presented in Table 1. All three forms of the
heterodimer have similar favorable enthalpy change (DH). The
thermodynamic basis for the difference in affinity is the larger
unfavorable entropy change (DS) observed in SRC1 binding to
CAR(meclizine):RXR compared with SRC1 binding to CAR
(TCPOBOP):RXR.
Conformational Differences within the CAR:RXR, CAR
(TCPOBOP):RXR, and CAR(meclizine):RXR Complexes
Comparative binding data shows that CAR(TCPOBOP):RXR
exhibits a stronger affinity for SRC1 coactivator peptide than
the CAR(meclizine):RXR complex. To determine a structural
basis for these results, we utilized steady-state quenching of
intrinsic tryptophan fluorescence of CAR:RXR to monitor
changes in conformation upon ligand binding. Upon titrating
TCPOBOP into the CAR:RXR heterodimeric LBD complex, there
is a dose-responsive decrease in fluorescence of this protein
complex. Since the CAR LBD sequence does not contain any
tryptophan residues and an excitation wavelength of 295 nm is
chosen to minimize the contribution from tyrosine residues, the
TCPOBOP-induced conformational changes are transmitted
from CAR across the CAR:RXR interface to the two tryptophan
residues on RXR (Figures 2A and 2B). However, these conforma-
tional changes do not appear to significantly affect 9-cis-retinoic
acid (9c) binding to CAR:RXR (see Figure S1 available online). In
addition, we determined the effect of ligand binding on each
tryptophan on RXR by titrating TCPOBOP into CAR:(W282F)
RXR and CAR:(W305F)RXR (Figure S2). There is a strong
dose-dependent increase in tryptophan quenching induced by
TCPOBOP on the CAR:(W282F)RXR mutant but no significant
response to the ligand by the CAR:(W305F)RXR mutant (Fig-
ure S2A). This suggests that while W305 in RXR is within the
allosteric pathway that is regulated by TCPOBOP, the environ-
ment of W282 does not undergo significant changes in the
presence of TCPOBOP.
Curiously, titrations of meclizine into CAR:RXR result in no
significant changes in the fluorescence spectra (Figure 2B).
Therefore, although both TCPOBOP and meclizine function as
mCAR agonists, the molecular mechanisms of CAR(TCPOBOP)
and CAR(meclizine) transactivation are not identical.
To identify specific structural features in CAR:RXR that
rearrange upon ligand binding and to distinguish between
CAR(TCPOBOP):RXR and CAR(meclizine):RXR, we performed
comprehensive differential, solution phase amide HDX MS
experiments on the CAR:RXR, CAR(TCPOBOP):RXR and CAR
(meclizine):RXR LBD complexes. For each receptor(ligand)
complex, differential HDX kinetics are determined by comparing
the kinetics of individual peptic peptides derived from the
complex to the corresponding peptic peptides generated from
the unliganded receptor.
Amide exchange kinetics of peptides representative of 76
regions of the CAR LBD within CAR:RXR and CAR(TCPOBOP):
RXR were compared for the two protein complexes (Figure 3A;
Figure S3A). From the same data sets, HDX kinetics were
determined and compared for peptides representative of 84
segments of RXR in the CAR:RXR and CAR(TCPOBOP):RXR
complexes (Figure 3B; Figure S3B). We observe statisticallys reserved
Table 1. Thermodynamic Parameters for SRC1 Peptide Binding to CAR:RXR in the Presence of Indicated Ligands
Ligand Kd (mM) DH (kcal/mol) -TDS (kcal/mol) DG (kcal/mol) n
TCPOBOPa 0.60 ± 0.10 10.0 ± 0.3 1.5 8.5 0.98 ± 0.07
Meclizine 0.91 ± 0.14 9.9 ± 0.3 1.7 8.2 0.95 ± 0.08
Nonea 4.9 ± 0.7 10.0 ± 0.4 2.8 7.2 1.03 ± 0.06
Determined at 25C and pH 7.2 as described in Experimental Procedures. The reported values are the average of at least three experiments and the
errors are the standard deviation.
aOriginally reported by Wright et al. (2007).
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Critical Helix 11 Dynamics in CARsignificant changes in HDX kinetics in three specific subdomains
of CAR. Peptides encompassing helices H20 and H20’ as well
as parts of helix H3 (residues 143–178) show significant protec-
tion from exchange in CAR(TCPOBOP):RXR compared with
CAR:RXR. In addition, there are substantial reductions in
exchange kinetics within the sequences that comprise helix H4
and parts of the b sheet, helix H6 and helix H7 (residues 199–Figure 2. TCPOBOP Binding to CAR Results in a Conformational
Change in RXR
(A) Change in intrinsic tryptophan fluorescence of RXR is monitored in
response to increasing levels of CAR ligand.
(B) TCPOBOP elicits a dose-responsive change in RXR fluorescence while
meclizine does not.
See also Figures S1 and S2.
Structure 19,210 and 228–249). The most significant reductions in HDX
behavior of the CAR(TCPOBOP) complex are seen within the
region encompassing helices H10, H11, and H12 (residues
327–358). These results reflect the extensive network of hydro-
phobic interactions between TCPOBOP and CAR that stabilize
AF-2 in the active conformation as observed in the structure of
CAR(TCPOBOP):RXR(9c) (Suino et al., 2004). In this structure,
the TCPOBOP A-ring is sandwiched between CAR Y234 and
CAR F227 and the C-ring is sandwiched between CAR Y336
and F244. The C-ring of TCPOBOP also interacts directly with
AF-2 (L353) and the linker helix (L346 and T350). These results
show a strong correlation between the HDX data from the CAR
(TCPOBOP) complex displaying regions with significantly
reduced exchange kinetics and the CAR ligand-binding pocket
in the CAR(TCPOBOP):RXR(9c) structure.
To examine the impact of TCPOBOP binding on the conforma-
tional dynamics of RXR within the CAR:RXR heterodimer, we
compare the exchange kinetics of all 84 RXR peptides between
the CAR:RXR and CAR(TCPOBOP):RXR. Interestingly, we
observe that RXR peptides in the region 416–432 display a signif-
icant reduction in HDX kinetics in CAR(TCPOBOP):RXR (Fig-
ure 3B; Figure S3B). These amino acids represent a large
segment of helix H10 of RXR which forms the dimerization inter-
face between CAR and RXR (Suino et al., 2004). In summary,
residues from both the CAR and RXR dimerization interface
display differential exchange kinetics when comparing CAR:RXR
with the CAR(TCPOBOP):RXR complex. Taken together, data
from HDX and fluorescence titrations suggest that TCPOBOP-
binding results in a perturbation of the conformational dynamics
within the heterodimer interface as well as conformational
changes near the RXR ligand-binding pocket.
We analyzed exchange kinetics for 76 regions of CAR within
the CAR(meclizine):RXR and CAR:RXR complexes (Figure 3C;
Figure S3A). Additionally, we compare HDX behavior for 84
regions of RXR within the CAR:RXR and CAR(meclizine):RXR
complexes (Figure S3B). The first of two regions within CAR(me-
clizine):RXR that are significantly protected to exchange when
compared with unliganded CAR:RXR includes a segment of
the b sheet and all of helix H6 (residues 228–245). The second
protected region of CAR(meclizine):RXR includes helices
H10/11 and H12 (residues 327–358) (Figure 3C). As mentioned
previously, helix H10/11 is the major contributor to the dimer
interface in CAR:RXR and H12 forms the AF-2 subdomain that
is critical to its interactions with SRC1. As predicted by fluores-
cence quenching experiments (Figure 2), and in contrast to
CAR(TCPOBOP):RXR, there are no significant differences in
exchange kinetics in RXR within the CAR(meclizine):RXR and
CAR:RXR complexes (Figure S3B).37–44, January 12, 2011 ª2011 Elsevier Ltd All rights reserved 39
Figure 3. Perturbations in HDX Data for
CAR and RXR LBDs
Cartoon rendition of percent reduction in HDX of
ligand bound CAR:RXR heterodimer complex
relative to unliganded receptor. Increasing protec-
tions from deuterium exchange are represented as
color gradient from light to dark blue as shown.
TCPOBOP is shown as an orange space-filled
model.
(A) CAR portion of CAR(TCPOBOP):RXR (76
peptides).
(B) RXR portion of CAR(TCPOBOP):RXR (84
peptides).
(C) CAR portion of the CAR(meclizine):RXR (76
peptides).
(D) Residues within the encircled region in the
unliganded CAR LBD model are mutated and
tested for activity.
See also Figure S3.
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Critical Helix 11 Dynamics in CARStabilization of CAR H10/11 Is Proportional to
Transactivation and Coactivatior Recruitment
Subtle differences in H/D exchange patterns within helices
H10–H12, which contains the AF-2 region, are evident between
the two ligand complexes. For instance, the C-terminal region
of helix H10 (residues 330–338) indicate lesser mobility of
CAR(TCPOBOP):RXR (exchange level =32%) than CAR(mecli-
zine):RXR (exchange level = 10%) (Figure S3A). At the AF2,
the most prominent differences between the two liganded
complexes are in residues 338–343 preceding the AF2 (helix
H12). These residues form a short a helix (H11) in the inverse
agonist bound structure of CAR (Moore, 2005) but are part of
the longer H10 observed in the CAR(TCPOBOP):RXR structure.
We introduced site-specific mutations within helix H11 to
investigate the role of this subdomain on the transactivation of
CAR. TheCARGlu339 forms a hydrogenbondwith the backbone
amide of Gln245, presumably contributing to the stability of the
active-state conformation of CAR (Shan et al., 2004). Also,
Leu340 and Leu343 extend into the apolar ligand-binding pocket
and can form hydrophobic interactions with residues within the
interior of the protein. Thus, alanine substitutions of Glu339,
Leu340, and Leu343 should eliminate these interactions resulting
in a less constrained helix H11. As predicted, we observe that
E339A (Shan et al., 2004), L340A and L343A each substantially
decreases CAR transactivation in transfected CV-1 cell-based
reporter gene assays (Figure 4A). Transactivation by these CAR
mutants is rescued by exogenously added TCPOBOP to wild-
type agonist-bound levels. We also reason that the substitution
of Leu340 and Leu343 with residues capable of stronger apolar
interactions with the CAR apolar ligand-binding pocket would
constrain helix H11 to a greater extent than wild-type CAR. To
test the hypothesis that the mobility of helix H11 can regulate40 Structure 19, 37–44, January 12, 2011 ª2011 Elsevier Ltd All rights reservedr
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tactivity, we designed L340F and L343F
mutants based on the twoCAR structures
(Shan et al., 2004; Suino et al., 2004).
Once again as predicted, the L340F and
L343F CAR mutants exhibit enhanced
transactivation when compared with
wild-type CAR, presumably due toincreased interactions of the bulkier phenylalanine side chain
with the apolar CAR ligand-binding pocket. Therefore, stronge
interactions between the L340F and L343F on helix H11 and
the main body of CAR can reduce the dynamics of this helix
and this corresponds to higher transactivation by these mutants
To relate the conformational mobility of helix H11 observed by
HDX to the transactivation of the CAR helix H11 mutants, we
characterized coactivator binding by these CAR mutants. The
affinity of (L343A)CAR:RXR for the SRC1 NR box 2 peptide is
lower than wild-type CAR, as suggested by the transactivation
profile for this mutant (Figures 4B and 4C). Additionally, this
mutant displays appreciably higher unfavorable entropy (TDS
(Table 2). In the presence of TCPOBOP, the affinity of (L343A
CAR:RXR for the 13-mer SRC1 peptide is comparable to wild-
type CAR(TCPOBOP):RXR (Table 2). Again, in close agreemen
with the transactivation assay, (L343F)CAR:RXR displays signif-
icantly greater affinity for coactivator and lower unfavorable
entropy compared with the wild-type complex (Table 2). Also
the affinity of (L343F)CAR(androstenol):RXR for the SRC1
peptide is similar to wild-type CAR(androstenol):RXR (Table 2)
These results provide further support for the hypothesis tha
the local dynamics of H11 plays a critical role in regulating
CAR transactivation. It is likely that TCPOBOP imparts greate
stability to this region and that this provides the structural basis
for the higher levels of transactivation and coactivator binding by
CAR(TCPOBOP):RXR than by the unliganded CAR:RXR or CAR
(meclizine):RXR complexes.
DISCUSSION
Since CAR is active in the unliganded state, displays increased
transactivation in the presence of meclizine and highes
Figure 4. Transactivation and Coactivator Binding Assays of CAR:RXR
(A) b) Luciferase reporter assay showing ligand (TCPOBOP) mediated CAR:RXR transactivation of the LXRE-TK-Luc reporter plasmid in CV-1 cells. Results are
reported in relative luciferase units (RLU).
(B and C) (B) Binding isotherms from titrations of SRC1 peptide into unliganded (L343A)CAR:RXR and (L343F)CAR:RXR and (C) summary of the SRC1 binding
assay.
Structure
Critical Helix 11 Dynamics in CARtransactivation in the presence of TCPOBOP, it is an ideal protein
to study the relationship of conformational dynamics and activity
in NRs. We have compared transcriptional activation, coactiva-
tor recruitment, and conformational dynamics of CAR:RXR in
the presence of two functionally distinct agonists. Cell-based
reporter gene assays and ITC experiments show that TCPOBOP
elicits greater transactivation and that this increase is propor-
tional to the difference in affinity for SRC1. Comprehensive anal-
ysis of differential HDX behavior of the two ligand-bound formsStructure 19,clearly shows that the impact of TCPOBOP on the conforma-
tional dynamics of the CAR structure is broader and of greater
magnitude than that of meclizine. This result is surprising since
the two ligands are very similar in molecular size and chemical
structure (Figure 1A). It is possible that meclizine does not
make as many efficient contacts within the CAR ligand-binding
pocket as compared with TCPOBOP or that the CAR(meclizine)
complex does not establish the intricate layers of interactions
observed in the CAR(TCPOBOP) structure. Additionally, there37–44, January 12, 2011 ª2011 Elsevier Ltd All rights reserved 41
Table 2. Thermodynamic Parameters for SRC1 Peptide Binding to the Indicated CAR:RXR Complexes
Complex Kd (mM) DH (kcal/mol) -TDS (kcal/mol) DG (kcal/mol) n
L343A (no ligand) 14 ± 1.7 10.6 ± 0.5 4.0 6.6 1.0 ± 0.13
L343A(TCPOBOP) 2.0 ± 0.24 11.5 ± 0.8 3.7 7.8 0.92 ± 0.14
L343F(no ligand) 0.92 ± 0.05 8.5 ± 0.2 0.30 8.2 0.97 ± 0.05
L343F (androstenol) 4.2 ± 0.29 10.0 ± 0.2 2.7 7.3 1.0 ± 0.04
Determined at 25C and pH 7.2 as described in Experimental Procedures. The reported values are the average of at least three experiments and the
errors are the standard deviation.
Figure 5. Comparison of CAR LBD Structures
(A) Structure of the CAR(androstenol) complex (REF).
(B) Proposed model for the structure of unliganded CAR based on the HDX
data and site-directed mutagenesis studies for residues 338–343.
(C) Structure of the CAR(TCPOBOP) complex (REF). The circled regions have
different conformations in the CAR(androstenol) and CAR(TCPOBOP) struc-
tures. Ligands are shown in mesh format.
Structure
Critical Helix 11 Dynamics in CARare more rotatable bonds within the meclizine structure which
can allow it to adapt more readily to the CAR ligand-binding
pocket unlike the relatively rigid TCPOBOP which can bind
CAR more strongly but can also restrict the dynamics of the
protein.
The global HDX kinetics observed for these three complexes
shows that the CAR:RXR complex is more dynamic with the rank
order of CAR:RXR > > CAR(meclizine):RXR > CAR(TCPOBOP):
RXR, and that it follows the same pattern as the values for TDS
observed upon binding the LXXLL coactivator peptide (Table 1).
This parallel suggests that, globally, the higher affinity for SRC1
results from a reduction in unfavorable entropy. The binding of
the ligand TCPOBOP (and to a lesser extent meclizine) restricts
the conformational dynamics of the protein. Thus, coactivator
binding is accompanied by a smaller net change in dynamics of
CAR and a smaller positive TDS component to the interaction.
Since DS values depend on other factors in addition to degrees
of freedomof the polypeptide chain (e.g., solvent reorganization),
any correlation between DS and dynamics must include these
factors. Nonetheless, the coactivator peptide binding and HDX
data when taken together suggest that the overall reduction in
protein motion is correlated with higher affinity for SRC-1 by
CAR:RXR.
Besides the global properties observed, there are two specific
areas of difference in the HDX data that distinguish TCPOBOP
from meclizine. First, the binding of TCPOBOP to CAR also
impacts the dynamics of RXR in CAR:RXR. This is not surprising
given the large conformational changes in the CAR helix H10
which forms a significant portion of the heterodimer interface.
Second, the greatly reduced HDX kinetics within helix H10/11
in CAR(TCPOBOP):RXR and the data from mutagenesis studies
of residues within this region show that reducing mobility of this
helix is a key component of the increase in activity by CAR
agonist. Observations that regions within the LBD other than
AF-2 can bemajor determinants of coactivator affinity and trans-
activation levels have been reported previously in the androgen
receptor (Estebanez-Perpina et al., 2007), estrogen receptor
(Dai et al., 2008), and PPARg (Bruning et al., 2007; Choi et al.,
2010).
The HDX and H11 mutagenesis data also provide insight into
the structure of unliganded CAR:RXR (which has not been
reported) as well as dynamic and conformational changes asso-
ciated with the transitions between the active and very active
states of CAR. The relatively shorter H12 in CAR compared
with other NRs and the resulting interaction between the
C-terminal carbonyl interacting with the side chain of K205
(Dussault et al., 2002) is understood to position helix H12 in the
active position in the unliganded protein resulting in its constitu-42 Structure 19, 37–44, January 12, 2011 ª2011 Elsevier Ltd All righttive activity. This helix H12 conformation is retained in the CAR
(TCPOBOP) complex (Suino et al., 2004). In the presence of
the inverse agonist, androstenol, helix H10 dissociated into
two helices with the C-terminal residues (338–343) forming the
short H11 (Shan et al., 2004). The significant differences in
mobility observed in the H/D exchange data for residues 338–
343 suggest that in the unliganded state H10 may more closely
resemble the CAR(androstenol) structure with a shorter, more
mobile, helix H11. Thus, unliganded, active CAR may have
a conformation that contains a short H11 similar to the inactive
CAR(androstenol) structure but with helix H12 in an orientation
similar to the very active CAR(TCPOBOP) conformation (Fig-
ure 5). In the CAR(TCPOBOP):RXR complex helices H10 and
H11 fuse into a single helix H10. The L340F and L343F CAR
mutants appear to mimic TCPOBOP in stabilizing helix H11
which leads to enhanced coactivator recruitment and increases
the levels of CAR transactivation.
In summary, these results provide insight into the mechanism
of graded modulation of CAR activity for structurally similar
agonists. It remains to be determined whether these mecha-
nisms are common to other NRs or unique to a subset of NR
family members. For instance, studies on the estrogen receptor
have indicated that allosteric communication between dimeric
partners can be mediated via helix H11 (Nettles et al., 2004).
More importantly, these results provide the foundation for
designing compounds that target CAR with varying degrees of
agonist activity.s reserved
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Protein Expression and Purification
Protein was prepared as described previously (Wright et al., 2007). In brief, the
mCAR LBD (residues 117–358) was subcloned into pET15b (Novagen) with an
N-terminal hexahistidine tag frommCAR cDNA provided by B.M. Forman. The
human RXR LBD (residues 225–462) in pACYC184 was a gift from B. Wisely
(Glaxo Smith-Kline, Inc.). The plasmids of CAR and RXR were cotransformed
into Escherichia coli BL21(DE3) Gold cells (Novagen) and coexpressed for
20 hr at 20C after induction with 0.5 mM IPTG. The cells were lysed by French
press. The CAR:RXR heterodimer was purified by affinity chromatography
using Ni-NTA (QIAGEN) followed by size-exclusion chromatography on
a Superdex S75 column (GE Healthcare). The mobile phase for size-exclusion
chromatography consisted of 20 mM Tris-HCl buffer (pH 8.0), 250 mM NaCl,
2.5 mM EDTA, 5.0 mM DTT for fluorescence and HDX experiments and
50 mM HEPES (pH 7.5), 125mM KCl, and 2 mM TCEP for ITC experiments.
Reporter Gene Assays
CV-1 cells were maintained in DMEM/F-12 media containing 10% fetal bovine
serum and 1000U/ml penicillin and 1mg/ml streptomycin. Immediately prior to
the assay, the media was changed to DMEM/F-12 with 10% charcoal-dextran
treated FBS and no antibiotics. Lipofectamine (Invitrogen) was used to trans-
fect cells with 50 ng/well pCMX mCAR, 100 ng/well pCMV-TK-luc containing
three copies of either retinoid acid receptor b2 response element (bRE) or liver
X receptor response element (LXRE) and 25 ng of pRL CMV expressing renilla
luciferase as an internal control. The cells were dispensed on 96-well plates
and ligands were added 4 hours after transfection. The ligand concentrations
used were TCPOBOP (1.0 mM), androstenol (10 mM), and meclizine (20 mM).
After 36 hr, cells were lysed. Activity was determined using the dual luciferase
assay kit (Promega) following the manufacturer’s instructions. The reported
results are the average from three separate experiments and the error bars
represent the standard deviation.
Isothermal Titration Calorimetry
Experiments were performed as described previously using the Microcal VP-
ITC instrument (Wright et al., 2007). In brief, 100–400 mM SRC1 box 2 peptide
was titrated into 8–36 mM CAR:RXR LBDs in 50 mM HEPES (pH 7.4), 125 mM
KCl, and 1 mM TCEP. A 4-fold excess of TCPOBOP or a 10-fold excess of
meclizine was included where indicated. Data were analyzed using the one-
site binding model in the Origin 7.0 software provided with the instrument.
The reported results are the average from four separate experiments and the
error bars represent the standard deviation.
Hydrogen/Deuterium Exchange Analysis
Solution phase amide HDX was performed on liganded and unliganded
CAR:RXR LBD heterodimers using a fully automated system that is described
elsewhere (Busby et al., 2007; Chalmers et al., 2006). The changes reported in
HDX are from direct comparisons between CAR(ligand):RXR to the corre-
sponding regions within the unliganded CAR:RXR. In brief, 4 ml of a 10 mM
protein solution containing either the copurified, preformed CAR:RXR hetero-
dimer or CAR:RXR bound to either meclizine or TCPOBOP (20 mM Tris-Cl
[pH 8], 250 mM NaCl, 5 mM DTT) was diluted up to 20 ml with D2O dilution
buffer (20 mM Tris-Cl [pH 8], 250 mM NaCl, 5 mM DTT) and incubated at
4C for the following periods of time: 10, 30, 60, 300, 900, and 3600 s.
Following deuterium on-exchange, unwanted forward and back exchange
was minimized and the protein was denatured by dilution to 50 ml with 1%
TFA in 3 M Urea (held at 1C). The protein sample was then passed across
an immobilized pepsin column (prepared in house) at 200 ml/min (0.1% TFA,
1C) and the resulting peptides were trapped onto a C18 trap column (Microm
Bioresources). Peptides were gradient eluted (4% CH3CN to 40% CH3CN,
0.3% formic acid over 15 min at 2C) over a 2.1 mm 3 50 mm C18 reverse
phase HPLC column (Hypersil Gold, Thermo Electron) and electrosprayed
directly into a high resolution orbitrapmass spectrometer (LTQ-Exactive, Ther-
moElectron, San Jose CA). Data were processed using in-house software
(Pascal et al., 2006, 2007, 2009) and Microsoft Excel followed by visualization
with pyMol (DeLano Scientific, South San Francisco CA). For the differential
analysis between the unliganded and meclizine bound forms of the CAR:RXR,
average percent deuterium incorporation was calculated for 76 regions of theStructure 19,CAR portion and 84 regions of the RXR portion of the CAR:RXR heterodimer in
either its unliganded or meclizine bound state following 10, 30, 60, 300, 900,
and 3600 s of on-exchange with deuterium. In addition, for the differential anal-
ysis between the unliganded and TCPOBOP bound forms of the CAR:RXR,
average percent deuterium incorporation was calculated for 76 regions of
the CAR and 84 regions of RXR in either its liganded or TCPOBOP bound state
following 10, 30, 60, 300, 900, and 3600 s of on-exchange with deuterium. To
determine differences in exchange between the CAR portions of the unli-
ganded and the ligand bound CAR:RXR, the average percent deuterium
values for all regions of the CAR from the unliganded CAR:RXR heterodimer
were subtracted from the average percent deuterium values of the identical
CAR regions from the CAR:RXR heterodimer bound to either meclizine or
TCPOBOP. The same procedure was used to determine differences in
exchange between the RXR portions of the heterodimer in either its unliganded
or ligand bound states.
Ligand Binding Assays
Binding wasmeasured bymonitoring the decrease in intrinsic tryptophan fluo-
rescence upon addition of ligand. For binding of CAR ligands, protein was
diluted to a concentration of 2.0 mM with fluorescence buffer (3% DMSO,
20 mM Tris-HCl [pH 8.0], 150 mM NaCl). Protein was then degassed for
15 min. Titrations were performed on the Perkin Elmer LS55 spectrofluorom-
eter. Scans were performed using an excitation wavelength of 295 nm and
emission scan of 305–400 nm. The excitation and emission slit widths were
8.0 nm. Either DMSO or ligand was added in 2 ml increments into a 2.5 ml
protein solution. Titrations of 9-cis-retinoic acid (9c) into CAR:RXR were per-
formed in a similar manner except a protein concentration of 0.5 mM was
used and the excitation and emission slit widths were 4.0 nm. Control exper-
iment titrating TCPOBOP and meclizine into 2.0 mM molecular tryptophan
showed no effect on fluorescence.
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